Ignite Creation Date:
2025-12-25 @ 12:39 AM
Ignite Modification Date:
2026-01-02 @ 6:56 AM
Study NCT ID:
NCT01617967
Status:
COMPLETED
Last Update Posted:
2024-04-19
First Post:
2012-06-07
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Safety and Tolerability of Patisiran (ALN-TTR02) in Transthyretin (TTR) Amyloidosis
Sponsor:
Alnylam Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2012-05
Start Date Type:
None
Primary Completion Date:
2013-10
Primary Completion Date Type:
ACTUAL
Completion Date:
2014-01
Completion Date Type:
ACTUAL
First Submit Date:
2012-06-07
First Submit QC Date:
None
Study First Post Date:
2012-06-13
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2018-08-30
Results First Submit QC Date:
None
Results First Post Date:
2018-11-21
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2017-07-17
Disp First Post Date Type:
ACTUAL
Last Update Submit Date:
2024-04-17
Last Update Post Date:
2024-04-19
Last Update Post Date Type:
ACTUAL